PANGYO, SOUTH KOREA -- Huonslab, a subsidiary of Huons Global (KOSDAQ: 084110), announced on December 10th the successful enrollment and administration of the first patient in its pivotal Phase 1 clinical study of Hydizyme™ (recombinant human natural hyaluronidase PH20) in South Korea.

This milestone represents a major step in Huonslab’s commitment to introducing Hydizyme™ to Korea and the U.S. market in a timely and strategic way.

Hydizyme™ (rHuPH20) is a highly purified recombinant human natural hyaluronidase PH20 designed to enhance the dispersion and absorption of other co-administered drugs and fluids.

The ongoing Phase 1 clinical study is a multicenter, double-blind, randomized, and placebo-controlled study aiming to evaluate the safety and potential allergic reactions associated with Hydizyme™ (HLB3-002) in 243 healthy volunteers.

“We are delighted to announce the enrollment and administration of our first patient, marking a significant milestone in our unwavering commitment to securing approval and ensuring the timely launch of Hydizyme™ in both South Korea and the United States. Hydizyme™ is poised to revolutionize the global market with its recombinant human natural hyaluronidase PH20-based approach, manufactured by our proprietary process-patented SC drug delivery technology, HyDIFFUZE™,” said Dr. Young Sun Lee, Chief Business Officer of Huonslab.

Hyaluronidases are extensively utilized in various medical applications, including enhancing subcutaneous drug delivery, facilitating fluid administration in emergency care, improving outcomes in ophthalmology, aesthetics, and dermatology, and reducing pain associated with co-administered local anesthetics.